Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Edaravone: a new treatment for ALS on the horizon?

Literature DB >> 28522180

Edaravone: a new treatment for ALS on the horizon?

Orla Hardiman¹, Leonard H van den Berg².

Abstract

Entities: Chemical Disease

Mesh：

Substances：

Year: 2017 PMID： 28522180 DOI： 10.1016/S1474-4422(17)30163-1

Source DB: PubMed Journal: Lancet Neurol ISSN： 1474-4422 Impact factor: 44.182

Keyword Cloud
Cited

× No keyword cloud information.

30 in total

1. Neuron-targeted caveolin-1 improves neuromuscular function and extends survival in SOD1^G93A mice.

Authors: Atsushi Sawada; Shanshan Wang; Minyu Jian; Joseph Leem; Jesse Wackerbarth; Junji Egawa; Jan M Schilling; Oleksandr Platoshyn; Alice Zemljic-Harpf; David M Roth; Hemal H Patel; Piyush M Patel; Martin Marsala; Brian P Head
Journal: FASEB J Date: 2019-03-20 Impact factor: 5.191

Review 2. Neurotheranostics as personalized medicines.

Authors: Bhavesh D Kevadiya; Brendan M Ottemann; Midhun Ben Thomas; Insiya Mukadam; Saumya Nigam; JoEllyn McMillan; Santhi Gorantla; Tatiana K Bronich; Benson Edagwa; Howard E Gendelman
Journal: Adv Drug Deliv Rev Date: 2018-10-26 Impact factor: 15.470

Review 3. Exploring the genetics and non-cell autonomous mechanisms underlying ALS/FTLD.

Authors: Hongbo Chen; Mark W Kankel; Susan C Su; Steve W S Han; Dimitry Ofengeim
Journal: Cell Death Differ Date: 2018-02-19 Impact factor: 15.828

Review 4. Pain Phenotypes in Rare Musculoskeletal and Neuromuscular Diseases.

Authors: Anthony Tucker-Bartley; Jordan Lemme; Andrea Gomez-Morad; Nehal Shah; Miranda Veliu; Frank Birklein; Claudia Storz; Seward Rutkove; David Kronn; Alison M Boyce; Eduard Kraft; Jaymin Upadhyay
Journal: Neurosci Biobehav Rev Date: 2021-02-10 Impact factor: 9.052

5. Edaravone, a Synthetic Free Radical Scavenger, Enhances Alteplase-Mediated Thrombolysis.

Authors: Kiyoshi Kikuchi; Kentaro Setoyama; Ko-Ichi Kawahara; Tomoka Nagasato; Takuto Terashi; Koki Ueda; Kazuki Nakanishi; Shotaro Otsuka; Naoki Miura; Hisayo Sameshima; Kazuya Hosokawa; Yoichiro Harada; Binita Shrestha; Mika Yamamoto; Yoko Morimoto-Yamashita; Haruna Kikuchi; Ryoji Kiyama; Chinatsu Kamikokuryo; Salunya Tancharoen; Harutoshi Sakakima; Motohiro Morioka; Eiichiro Tanaka; Takashi Ito; Ikuro Maruyama
Journal: Oxid Med Cell Longev Date: 2017-11-10 Impact factor: 6.543

Edaravone: a new treatment for ALS on the horizon?

1. Neuron-targeted caveolin-1 improves neuromuscular function and extends survival in SOD1^G93A mice.

Review 2. Neurotheranostics as personalized medicines.

Review 3. Exploring the genetics and non-cell autonomous mechanisms underlying ALS/FTLD.

Review 4. Pain Phenotypes in Rare Musculoskeletal and Neuromuscular Diseases.

5. Edaravone, a Synthetic Free Radical Scavenger, Enhances Alteplase-Mediated Thrombolysis.

Review 6. Current Advances and Limitations in Modeling ALS/FTD in a Dish Using Induced Pluripotent Stem Cells.

Review 7. Motor Neuron Gene Therapy: Lessons from Spinal Muscular Atrophy for Amyotrophic Lateral Sclerosis.

8. Risks and benefits of unapproved disease-modifying treatments for neurodegenerative disease.

9. Logistics and safety of edaravone treatment for amyotrophic lateral sclerosis: experience in Argentina.

Review 10. RNA-Targeted Therapies and Amyotrophic Lateral Sclerosis.

Edaravone: a new treatment for ALS on the horizon?

1. Neuron-targeted caveolin-1 improves neuromuscular function and extends survival in SOD1G93A mice.

Review 2. Neurotheranostics as personalized medicines.

Review 3. Exploring the genetics and non-cell autonomous mechanisms underlying ALS/FTLD.

Review 4. Pain Phenotypes in Rare Musculoskeletal and Neuromuscular Diseases.

5. Edaravone, a Synthetic Free Radical Scavenger, Enhances Alteplase-Mediated Thrombolysis.

Review 6. Current Advances and Limitations in Modeling ALS/FTD in a Dish Using Induced Pluripotent Stem Cells.

Review 7. Motor Neuron Gene Therapy: Lessons from Spinal Muscular Atrophy for Amyotrophic Lateral Sclerosis.

8. Risks and benefits of unapproved disease-modifying treatments for neurodegenerative disease.

9. Logistics and safety of edaravone treatment for amyotrophic lateral sclerosis: experience in Argentina.

Review 10. RNA-Targeted Therapies and Amyotrophic Lateral Sclerosis.

1. Neuron-targeted caveolin-1 improves neuromuscular function and extends survival in SOD1^G93A mice.